Cytori Therapeutics Inc  

(Public, NASDAQ:CYTX)   Watch this stock  
Find more results for CYTX
0.661
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.36 - 2.54
Open     -
Vol / Avg. 0.00/2.85M
Mkt cap 92.05M
P/E     -
Div/yield     -
EPS -0.55
Shares 125.76M
Beta 2.89
Inst. own 13%
Jul 31, 2015
Cytori Therapeutics Inc Annual Shareholders Meeting (Estimated) - 12:00PM EDT - Add to calendar
May 11, 2015
Q1 2015 Cytori Therapeutics Inc Earnings Call
May 11, 2015
Q1 2015 Cytori Therapeutics Inc Earnings Release
Mar 12, 2015
Q4 2014 Cytori Therapeutics Inc Earnings Call
Mar 12, 2015
Q4 2014 Cytori Therapeutics Inc Earnings Release
Mar 10, 2015
Cytori Therapeutics Inc at ROTH Conference
Mar 4, 2015
Cytori Therapeutics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -935.98% -491.81%
Operating margin -895.01% -426.92%
EBITD margin - -423.95%
Return on average assets -232.49% -92.52%
Return on average equity - -
Employees 78 -
CDP Score - -

Address

3020 Callan Rd
SAN DIEGO, CA 92121-1109
United States - Map
+1-858-4580900 (Phone)
+1-858-4580994 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytori Therapeutics, Inc. (Cytori) develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The Company’s research applications include stress, urinary incontinence, wound healing, fistula repair, burn, facial wasting, liver insufficiency, radiation injury, bone regeneration, kidney disease, spinal disc injury, periodontal disease, vocal cord paralysis and peripheral vascular disease. The Company’s drugs and clinical trials include: ATHENA, which is a drug for cardiovascular disease; ADVANCE, which is the Company’s trial for acute myocardial infarction in Europe; PRECISE, which is a clinical trial for chronic myocardial ischemia; APOLLO trial, which is a study for heart attack patients; RESTORE 2, which is a study trial for breast reconstruction, and RECOVER, which is used to evaluate Cytori Cell Therapy in Grade II tears of the hamstring muscle.

Officers and directors

David M. Rickey Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Marc H. Hedrick M.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Tiago Girao Chief Financial Officer, Vice President - Finance
Age: 35
Bio & Compensation  - Reuters
Seijiro N. Shirahama President , Asia Pacific
Age: 59
Bio & Compensation  - Reuters
Steven Kesten M.D. Executive Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters
Paul W. Hawran CPA Independent Director
Age: 62
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Gail K. Naughton Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Tommy G. Thompson J.D. Independent Director
Age: 73
Bio & Compensation  - Reuters